Kinase Inhibitor Market, By Product (Angiogenesis Inhibitor, mTOR Inhibitor, BRAF & MEK Inhibitor and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

The rising prevalence of cancer has been one of the major threats to the healthcare industry. It is accounted to be the second leading cause of mortality, worldwide. With the increasing life span and high life expectancy, the population of elderly people is expected to increase in future. Accumulation of genetic mutations with rising lifespan is expected to increase the chances of people developing cancer, thereby increasing the prevalence of cancer. Kinase inhibitor blocks the action of one or more protein kinases and add phosphate group to protein, and can modulate its function. Phosphorylation regulates many biological processes and kinase inhibitor can used to treat disease which are serious diseases like cancer due to its hyperactive protein kinases. These enzymes selectively block the action of other enzymes. The Kinase Inhibitor Market accounted for US$ 42.5 billion in 2020 and is estimated to be US$ 80.2 billion by 2030 and is anticipated to register a CAGR of 6.6%.

Impact of Covid-19 pandemic on market

Number of patients suffering from cancer is rising day by day. Due to lockdown the clinical trials were stopped and research labs were also affected during Covid-19. This report will quantify the impact of this pandemic on the diagnostics market.

Awareness about Kinase inhibitor

Awareness about kinase inhibitor and surge in product approvals are the major driving factors for this market. Investment from pharmaceutical companies also propel the market growth.

Increase in cancer patients

Increase in cancer patients worldwide triggers the market growth of kinase inhibitor and more research and development in this field also boost the market.

However, cost of treatment and lack of funds might hamper growth of the global market to a certain extent.

The global kinase inhibitor market is segmented based on product, distribution channel, and region.

On the basis of product, the global kinase inhibitor market is segmented into Angiogenesis Inhibitor, mTOR Inhibitor, BRAF & MEK Inhibitor and Others. Based on distribution channel, the target market is segmented into Hospital Pharmacies, Online Pharmacies and Others.

Regional Insights:

On region the global kinase inhibitor market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is considered dominating during the forecast period due to availability of all major key players in the region, awareness about new drugs for treatment, advancement in technologies and prevalence of cases in U.S. Europe is second dominating region in the market of kinase inhibitor.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global kinase inhibitor market report based on product, distribution channel, and region.

Global kinase inhibitor market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
    • Rest of Middle East & Africa

The key players operating in the global kinase inhibitor market includes Incyte Corporation, Glaxo SmithKline, AstraZeneca, Eisai Co., Ltd., Bristol-Myers Squibb, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Eisai Co., Ltd., Johnson & Johnson and F. Hoffmann-La Roche Ltd. Companies are continuously rising the production and supply of drugs to grow the market of kinase inhibitor.

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Incyte Corporation
• Glaxo SmithKline
• AstraZeneca, Eisai Co., Ltd.
• Bristol-Myers Squibb
• Bayer AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim GmbH
• Eisai Co., Ltd.
• Johnson & Johnson